Add to ORKGDuring recent discussions, it has been argued that stratified cost-effectiveness analysis has a key role in reimbursement decision-making and value-based pricing (VBP). It has previously been shown that when manufacturers are price-takers, reimbursement decisions made in reference to stratified cost-effectiveness analysis lead to a more efficient allocation of resources than decisions based on whole-population cost-effectiveness analysis. However, we demonstrate that when manufacturers are price setters, reimbursement or VBP based on stratified cost-effectiveness analysis may not be optimal. Using two examples – one considering the choice of thrombolytic treatment for specific patient subgroups and the other considering the extension of cov...
Implementation of reimbursement decisions is important to payers and manufacturers, however, evidenc...
In an effort to control rising drug costs, some health insurers have begun experimenting with method...
We use a simple theoretical model to compare alternative regulation regimes for the reimbursement of...
During recent discussions, it has been argued that stratified cost-effectiveness analysis has a key ...
During recent discussions, it has been argued that stratified cost-effectiveness analysis has a key ...
The cost-effectiveness of new health care technologies is conditional upon who receives what therapy...
In this article, we consider the problem of financing highly effective and cost-effective prescripti...
Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform dec...
Drawing on a pragmatist approach to pricing, this article discusses the impact of cost-effectiveness...
‘Value-based’ outcomes, pricing, and reimbursement are widely discussed as health sector reforms the...
Reimbursement of pharmaceuticals ought to provide both incentives for and reward innovation, as well...
RATIONALE: Stratified Medicine (SM) is becoming a natural result of advances in biomedical science a...
Value-based pricing (VBP) is well established in markets for common goods and services, but wide con...
Stratified medicine (SM) is an innovative treatment concept which has drawn major attention in the p...
The price of new brand-name prescription drugs has been rising fast in the United States. For exampl...
Implementation of reimbursement decisions is important to payers and manufacturers, however, evidenc...
In an effort to control rising drug costs, some health insurers have begun experimenting with method...
We use a simple theoretical model to compare alternative regulation regimes for the reimbursement of...
During recent discussions, it has been argued that stratified cost-effectiveness analysis has a key ...
During recent discussions, it has been argued that stratified cost-effectiveness analysis has a key ...
The cost-effectiveness of new health care technologies is conditional upon who receives what therapy...
In this article, we consider the problem of financing highly effective and cost-effective prescripti...
Health systems around world are increasingly adopting cost-effectiveness (CE) analysis to inform dec...
Drawing on a pragmatist approach to pricing, this article discusses the impact of cost-effectiveness...
‘Value-based’ outcomes, pricing, and reimbursement are widely discussed as health sector reforms the...
Reimbursement of pharmaceuticals ought to provide both incentives for and reward innovation, as well...
RATIONALE: Stratified Medicine (SM) is becoming a natural result of advances in biomedical science a...
Value-based pricing (VBP) is well established in markets for common goods and services, but wide con...
Stratified medicine (SM) is an innovative treatment concept which has drawn major attention in the p...
The price of new brand-name prescription drugs has been rising fast in the United States. For exampl...
Implementation of reimbursement decisions is important to payers and manufacturers, however, evidenc...
In an effort to control rising drug costs, some health insurers have begun experimenting with method...
We use a simple theoretical model to compare alternative regulation regimes for the reimbursement of...